Kridin, Khalaf http://orcid.org/0000-0001-9971-9151
Schonmann, Yochai
Tzur Bitan, Dana
Damiani, Giovanni
Peretz, Alon
Weinstein, Orly
Cohen, Arnon D.
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Article History
Accepted: 17 April 2021
First Online: 31 May 2021
Declarations
:
: Open access funding enabled and organized by Projekt DEAL. No sources of funding were received for the conduct of this study or the preparation of this article.
: Arnon D. Cohen served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. Khalaf Kridin, Yochai Schonmann, Dana Tzur Bitan, Giovanni Damiani, Alon Peretz, and Orly Weinstein have no conflicts of interest that are directly relevant to the content of this article.
: The study was approved by the institutional review board in accordance with the Declaration of Helsinki (approval code: 0212-17-COM).
: Not applicable.
: Not applicable.
: Not applicable
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: KK and ADC had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: KK and ADC. Acquisition, analysis, and interpretation of data: KK, DTB, and AP. Drafting of the manuscript: KK and YS. Critical revision of the manuscript for important intellectual content: KK, ADC, and DTB. Statistical analysis: OW and YS. Obtained funding: None. Administrative, technical, or material support: ADC and OW. Study supervision: KK and ADC.